The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A multicenter phase II study of S-1 combined with irinotecan (CPT-11) for patients with advanced/recurrent breast cancer.
U. Toh
No relevant relationships to disclose
N. Iwakuma
No relevant relationships to disclose
H. Otsuka
No relevant relationships to disclose
M. Takenaka
No relevant relationships to disclose
E. Ogo
No relevant relationships to disclose
T. Fujii
No relevant relationships to disclose
M. Tanaka
No relevant relationships to disclose
K. Shirouzu
No relevant relationships to disclose